ASH 2023 | TrAVeRse: acalabrutinib + venetoclax and rituximab for treatment-naïve MCL
Eliza Hawkes, FRACP, MD, MBBS, The Olivia Newton-John Cancer Wellness & Research Centre at Austin Health, Melbourne, Australia, introduces the TrAVeRse trial (NCT05951959), a Phase II, open-label, randomized study of acalabrutinib in combination with venetoclax and rituximab (AVR) in patients with treatment-naïve mantle cell lymphoma (MCL). Despite advances in the treatment of MCL, chemoimmunotherapy, which is associated with long-term toxicities, remains the primary treatment option for treatment-naïve patients. TrAVeRse will evaluate the efficacy of the chemotherapy-free AVR triplet combination, with the primary endpoint of measurable residual disease (MRD)-negative complete response (CR) rate at the end of induction. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Board of Directors/Advisory Committee: Novartis, Janssen, Merck Sharpe & Dohme, Gilead, Astra Zeneca, Roche, Bristol-Myers Squibb
Travel Expenses: Astra Zeneca, Antengene, Specialised Therapeutics
Speakers Bureau: Janssen, Astra Zeneca, Regeneron
Research Funding: Astra Zeneca, Merck KgA, Roche, Bristol-Myers Squibb
Honoraria: Specialised Therapeutics
Other: Novartis, Beigene
